Could a simple tablet stop epilepsy after a stroke?

NCT ID NCT07604350

Not yet recruiting Prevention Sponsor: First Affiliated Hospital of Wenzhou Medical University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a tablet called edaravone dexborneol can prevent epilepsy in people who have had a stroke and are at high risk. About 160 adults will receive either the tablet or a placebo for three months, starting within 48 hours of their stroke. Researchers will track seizures and brain activity over two years to see if the treatment helps.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Edaravone dexborneol sublingual tablets (edaravone 30 mg plus borneol 6 mg)
What this could lead to: If successful, this could provide a new way to prevent epilepsy in people who have had a stroke, reducing seizures and improving recovery.
What could go wrong: This is an early-stage trial with only 160 participants, so results may not apply to everyone. The treatment also has potential side effects, and it's not yet proven to work.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke structural epilepsy prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POST STROKE EPILEPSY POST-STROKE SEIZURE

Contacts and locations

Locations

The First Affiliated Hospital of Wenzhou Medical University

Wenzhou, Zhejiang, 325000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.